21626-43-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Amino-6-(benzylamino)-3-nitropyridine is used as a key intermediate in the synthesis of triaminopyridines, which are known for their anticonvulsant properties. These compounds are valuable in the development of medications for the treatment of epilepsy and other seizure disorders.
Used in the Synthesis of Flupirtine:
2-Amino-6-(benzylamino)-3-nitropyridine is also used as an impurity in the synthesis of Flupirtine (F598510), an analgesic medication. Flupirtine is prescribed for the relief of moderate to severe pain and is known to have a unique mechanism of action that involves interaction with calcium channels and the central nervous system.
Used in Central Analgesic Development:
As a substituted pyridine with central analgesic properties, 2-Amino-6-(benzylamino)-3-nitropyridine plays a crucial role in the development of new medications aimed at providing pain relief. Its potential use in the creation of novel analgesics makes it a valuable compound in the field of pharmaceutical research and development.

Upstream product

• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 100-46-9 benzylamine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 

Downstream Products

• 21630-55-7 N⁶-benzyl-pyridine-2,3,6-triaine 
• 21630-56-8 ethyl <2-amino-6-(benzylamino)pyridin-3-yl>carbamate hydrochloride 

Relevant academic research and scientific papers

Design of a novel and selective IRAK4 inhibitor using topological water network analysis and molecular modeling approaches

Protein kinases are deeply involved in immune-related diseases and various cancers. They are a potential target for structure-based drug discovery, since the general structure and characteristics of kinase domains are relatively well-known. However, the ATP binding sites in protein kinases, which serve as target sites, are highly conserved, and thus it is difficult to develop selective kinase inhibitors. To resolve this problem, we performed molecular dynamics simulations on 26 kinases in the aqueous solution, and analyzed topological water networks (TWNs) in their ATP binding sites. Repositioning of a known kinase inhibitor in the ATP binding sites of kinases that exhibited a TWN similar to interleukin-1 receptor-associated kinase 4 (IRAK4) allowed us to identify a hit molecule. Another hit molecule was obtained from a commercial chemical library using pharmacophore-based virtual screening and molecular docking approaches. Pharmacophoric features of the hit molecules were hybridized to design a novel compound that inhibited IRAK4 at low nanomolar levels in the in vitro assay.

Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2)

Neurodegenerative diseases share certain pathophysiological hallmarks that represent common targets for drug discovery. In particular, dysfunction of proteostasis and the resultant apoptotic death of neurons represent common pathways for pharmacological intervention. A library of aromatic carbamate derivatives based on the clinically available drug flupirtine was synthesized to determine a structure-activity relationship for neuroprotective activity. Several derivatives were identified that possess greater protective effect in human induced pluripotent stem cell-derived neurons, protecting up to 80% of neurons against etoposide-induced apoptosis at concentrations as low as 100 nM. The developed aromatic carbamates possess physicochemical properties desirable for CNS therapeutics. The primary known mechanisms of action of the parent scaffold are not responsible for the observed neuroprotective activity. Herein, we demonstrate that neuroprotective aromatic carbamates function to increase the Bcl-2/Bax ratio to an antiapoptotic state and activate autophagy through induction of beclin 1.

Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines

The synthesis of 2,3,6-triaminopyridine derivatives, representing a unique chemical structure for anticonvulsants, is described. The synthetic program was performed (a) to identify more potent analogs, (b) to determine structural properties controlling potency as well as neurotoxicity, and (c) to reduce the requirements for animal testing. As a result, besides other structural properties, the overall molecular lipophilicity (log k', octanol- coated column) explained changes in anticonvulsant potency and neurotoxicity. Mimicking the interaction of the amphiphilic triaminopyridines with biological membranes, NMR experiments in the presence of lecithin vesicles were conducted in order to measure the phospholipid-binding parameter log Δ(1/T2). Replacement of log k' with log Δ(1/T2) in the correlation analysis afforded a more significant equation describing the anticonvulsant activity of 21 derivatives.